Stocklore

Eli Lilly and Company (LLY)

Biotech & Health · US stock

Company overview

A pharma company posting blockbuster-scale growth with GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound). Its Alzheimer's drug pipeline is also drawing attention.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Eli Lilly and Company is classified under the Biotech & Health sector. See peers below.

ETFs holding Eli Lilly and Company

Per SEC N-PORT · 2026-03-31 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
13.74%
VOOVANGUARD 500 INDEX FUND
1.30%
SPY
1.30%
IVViShares Core S&P 500 ETF
1.30%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
1.25%
ITOTiShares Core S&P Total U.S. Stock Market ETF
1.15%
JEPIJPMorgan Equity Premium Income ETF
0.83%
RSPInvesco S&P 500 Equal Weight ETF
0.20%

LLY on Stocklore

  • Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
  • Sector-relative metrics — valuation and growth vs the Biotech & Health average
See full LLY analysis →

Peers · Biotech & Health

LLY FAQ

What is Eli Lilly and Company (LLY)?

A pharma company posting blockbuster-scale growth with GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound). Its Alzheimer's drug pipeline is also drawing attention.

What sector is Eli Lilly and Company in?

Eli Lilly and Company is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

Where can I analyze Eli Lilly and Company (LLY) stock?

On Stocklore you can see LLY's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

스톡로어 · CEO 이승재 · Business reg. no. 764-36-01607 · E-commerce permit 제2026-전주완산-0476호 · Tel 070-7954-4939 · 전북특별자치도 전주시 완산구 중산중앙로 21, 3층 302호 S120호